SAN DIEGO, Jan 10, 2011 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today announced its next generation of iSelect custom genotyping products that allow researchers to design custom arrays containing from 3,000 up to 1,000,000 markers, with the flexibility to add supplemental content to their array designs. The additional marker and add-on content capabilities enable researchers to draw on the latest advances from genome-wide association studies, next-generation whole-genome sequencing, and exome sequencing studies for variant confirmation, fine mapping, and target validation. Next generation iSelect also delivers the flexibility in plexity, pricing, and content that applied markets need to transition to the latest genomic tools.
"Next generation iSelect custom genotyping will facilitate more data generation, and at a lower price that will make our Infinium® assay available to a market segment not able to access it previously," said Christian Henry, General Manager of Life Sciences at Illumina. "We are especially excited about the product's new add-on content capabilities, which will allow customers to design new content for their existing custom arrays using markers found through ongoing GWAS and sequencing efforts. This feature is unique to Illumina's custom high-density arrays and provides a significant benefit to customers who want to add newly discovered content after the initial design period is completed."
iSelect custom genotyping arrays provide:
- Accurate and powerful data. The proven Infinium assay enables specificity and selectivity for more robust genotype calls and industry-leading data quality.
- Flexible design. Researchers can design arrays with content from any source and any species, as well as add content after the initial design is complete.
- Relevant custom content. Illumina's proprietary Assay Design Tool allows researchers to design arrays with the most relevant SNPs, CNVs, and insertions/deletions.
- Fast and cost-effective genotyping. Illumina's 24-sample iSelect format allows researchers to process thousands of samples per week, decreasing time to results.
iSelect products are available for order immediately. To learn more about Illumina's custom genotyping technologies, please visit www.illumina.com/cga.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected shipping date for the iSelect products. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Senior Manager, Public Relations
858-882-6822
wgrabill@illumina.com
